Autoantibodies to citrullinated fibrinogen compared with anti-MCV and anti-CCP2 antibodies in diagnosing rheumatoid arthritis at an early stage: data from the French ESPOIR cohort
Annals of Rheumatic Diseases,

Nicaise–Roland P et al. – In early arthritis, antibodies to citrullinated fibrinogen (AhFibA), anti–MCV and anti–CCP2 showed similar diagnostic sensitivity with a high diagnostic specificity and a similar high positive predictive value for rheumatoid arthritis (RA). Adding anticitrullinated peptides/protein antibodies (ACPA) to the 1987 ACR criteria significantly increased the number of patients classified as having RA, confirming the validity of the recent inclusion of the serological criterion in the ACR/EULAR criteria.

Methods
  • A diagnosis of RA (1987 American College of Rheumatology (ACR) criteria) was established at baseline in 497 patients and after a 2–year follow–up in 592 patients.
  • At baseline, antibodies to citrullinated fibrinogen (AhFibA), antimutated citrullinated vimentin (anti–MCV) and anticyclic citrullinated peptide (anti–CCP2) were assayed and the individual and combined diagnostic sensitivities and predictive values of the tests were determined.
  • Relationships between ACPA positivity and the 28–joint disease activity score and Health Assessment Questionnaire scores were analysed.

Results
  • At a diagnostic specificity of at least 98%, the three tests exhibited similar diagnostic sensitivities (47–48.5%).
  • When considering as positive patients with at least one positive test, the sensitivity increased to 53.5% with a probable loss of specificity.
  • Among the patients classified as having UA at baseline, 30% were positive for one ACPA, the positive predictive values for RA of the three tests ranging from 73% to 80% but increasing when two tests were associated.
  • Whatever the test used, the addition of ACPA positivity to the 1987 criteria enhanced their sensitivity by 6%, close to that of the 2010 ACR/European League Against Rheumatism (EULAR) criteria.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Rheumatology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Rheumatology Articles

1 Could ibuprofen be an anti-aging medicine? Buck Institute for Research on Aging News, December 22, 2014

2 Rituximab for the treatment of relapses in ANCA-associated vasculitis Arthritis & Rheumatism, August 1, 2014    Clinical Article

3 Mayo Clinic researchers: TNF inhibitors may increase cancer risk in the eye Mayo Clinic, November 19, 2014

4 Ten common mistakes in the management of lupus nephritis American Journal of Kidney Diseases, January 3, 2014    Clinical Article

5 Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: A meta-analysis Clinical Infectious Diseases, April 28, 2014    Evidence Based Medicine

6 Fish consumption and risk of rheumatoid arthritis: A dose-response meta-analysis Arthritis Research & Therapy, October 8, 2014    Evidence Based Medicine    Review Article

7 Identification of lymphoma predictors in patients with primary Sjögren's syndrome: A systematic literature review and meta-analysis Rheumatology International, June 5, 2014    Evidence Based Medicine    Review Article

8 Methotrexate and lung disease in rheumatoid arthritis – A meta-analysis of randomized controlled trials Arthritis & Rheumatism, December 27, 2013    Evidence Based Medicine    Review Article    Clinical Article

9 Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: A clinical observational study Rheumatology, February 11, 2014    Clinical Article

10 The association of serum anti-ribosomal P antibody with clinical and serological disorders in systemic lupus erythematosus: A systematic review and meta-analysis Lupus, November 26, 2014    Evidence Based Medicine    Review Article

11 Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: A multicentre, randomised, double-blind, non-inferiority trial versus celecoxib Annals of Rheumatic Diseases, January 23, 2015    Clinical Article

12 Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis Joint, Bone, Spine, July 3, 2014    Clinical Article

13 The comparative safety of TNF inhibitors in rheumatoid arthritis - a meta-analysis update of 44 randomized controlled trials American Journal of Medicine, October 6, 2014    Clinical Article

14 Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients Seminars in Arthritis and Rheumatism, January 5, 2015    Clinical Article

15 Intra articular injection with corticosteroids in patients with recent onset rheumatoid arthritis: subanalyses from the BeSt study Clinical Rheumatology, February 17, 2014    Clinical Article

16 A combination of celecoxib and famciclovir is efficacious in the treatment of fibromyalgia: Results of a phase IIa randomized, double-blind, placebo-controlled study American College of Rheumatology News, December 2, 2014    Clinical Article

17 Risk of malignancy in patients with giant cell arteritis and polymyalgia rheumatica: A systematic review and meta-analysis Seminars in Arthritis and Rheumatism, June 27, 2014    Evidence Based Medicine    Review Article

18 Coffee or tea consumption and the risk of rheumatoid arthritis: A meta-analysis Clinical Rheumatology, October 15, 2014    Clinical Article

19 Denosumab and osteonecrosis of the jaws: The pharmacology, pathogenesis and a report of two cases Australian Dental Journal, August 25, 2014

20 Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: A systematic review and meta-analysis Annals of Rheumatic Diseases, January 7, 2015    Evidence Based Medicine    Review Article

Indexed Journals in Rheumatology: Arthritis & Rheumatism, Annals of Rheumatic Diseases, Journal of Rheumatologymore

Looking for a physician job? Let us help!

Register now for our free job placement service.
A career consultant will contact you soon.
Click Here for more information.

Get Started Now!

Free-of-charge, no obligation.

Terms and Conditions For M3 Career Consult

By registering with the M3 Career Consult service you authorize M3 USA Corporation to represent you in your job search. The following is a summary of the terms of our service and our mutual obligations to help you find a job:

  • You designate M3 to act as your agent and represent you in your job search;
  • You will not pay us for this service
  • You will advise us of any companies or positions to which you apply or have applied;
  • You will advise us if you believe you are not capable of performing a position for which we submit you, or for which you interview;
  • You will keep all information we provide you about companies or positions strictly confidential;
  • You will promptly provide us with information we request of you;
  • You will make yourself reasonably available for phone, video and in-person conversations and interviews;
  • You will be truthful in all of your communications with us; and
  • You will advise us if anything above changes.
 

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List